Press Releases
Lesch-Nyhan Syndrome Market Size, Share & Trend | Industry Analysis Report, 2026

, 22 September 2018 -- The rising incidence and prevalence of Lesch-Nyhan Syndrome, increased research and development expenditure, and growing awareness among people are factors that drive the global Lesch-Nyhan Syndrome market.

Lesch–Nyhan Syndrome (LNS) is a rare genetic disorder caused by mutation of the HPRT1 gene. Mutation of the gene leads to deficiency of the enzyme hypoxanthine-guanine phosphoribosyl transferase 1. Insufficient level of this enzyme leads to overproduction and accumulation of uric acid in bodily fluids. Accumulation of uric acid damages the kidneys, the central nervous system, the joints, and other tissues. The excessive level of uric acid may cause gouty arthritis, kidney stone, or bladder stones. It may also lead to abnormal movements of involuntary muscles such as jerking, flexing, and flailing. It may cause behavioral disturbances.
Read Report Overview:
People suffering from Lesch–Nyhan Syndrome generally cannot walk, need assistance to sit, and mostly need a wheelchair. Self-injuries such as head banging and biting is the most common and typical behavioral pattern observed in patients with Lesch–Nyhan Syndrome. The condition primarily affects men, as the HPRT1 gene is located on the X chromosome. However, a few cases are reported in women also. The rate of prevalence of LNS is around 1 in 380,000 people.
To date, no treatment has been approved for use in patients with Lesch-Nyhan Syndrome. However, the current treatment focuses on relieving of symptoms and prevention of complications. Based on treatment, the global Lesch–Nyhan Syndrome market has been segmented into medication, dietary supplements, lithotripsy, behavioral therapy, surgery, and others (including deep brain stimulation). Medication generally includes use of allopurinol, baclofen, gabapentin, carbamazepine, and pain relievers (NSAIDs). The medication segment is expected to expand at a significant pace during the forecast period, owing to promising pipeline molecules and rising incidence of Lesch-Nyhan Syndrome.
The rising incidence and prevalence of Lesch-Nyhan Syndrome, increased research and development expenditure, and growing awareness among people are factors that drive the global Lesch-Nyhan Syndrome market. Though currently available therapeutic options are effective at managing and preventing Lesch-Nyhan Syndrome, challenges of treating Lesch-Nyhan Syndrome lie in the unpredictable response of every patient, representing a major unmet need in the global Lesch-Nyhan Syndrome market. On the other hand, disappointing results of promising pipeline molecules restrain the global Lesch-Nyhan Syndrome market.
Request Brochure of Report:
Geographically, the global Lesch–Nyhan Syndrome market has been categorized into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the global market during the forecast period, followed by Europe. Increasing incidence and prevalence of Lesch–Nyhan Syndrome, well-established health care infrastructure, rising research and development expenditure, growing adoption of advanced treatment options, and surging health care spending in North America and Europe propel the market in these regions. The market in Asia Pacific is expected to expand at a high CAGR during the forecast period. The market in the region is likely to be driven by wide patient base, increased incidence of Lesch–Nyhan Syndrome, rising awareness, and increased government initiatives toward improving health and developing health care infrastructure in India and China during the forecast period. The Lesch–Nyhan Syndrome market in Latin America and Middle East & Africa is anticipated to expand at a significant pace during the forecast period, owing to increasing investments by key market players in these regions.
Request For TOC :
Leading players operating in the global Lesch–Nyhan Syndrome market are Psyadon Pharma Boehringer Ingelheim GmbH, AstraZeneca plc, 3SBio, Selecta Biosciences, Teijin Pharma Ltd., Phoenix Pharmacologics, GlaxoSmithKline plc., Regeneron Pharmaceuticals, Novartis AG, Merck & Co. Inc., and Savient Pharmaceuticals.
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453

# # #

Submitted by Sandy Researcher, Transparency Market Research on Saturday, 22 September 2018 at 4:28 PM
Category: Health Care & Medical
Related News

Are Online Doctor Consultations the New Thing in Healthcare?
Wednesday, 24 Oct 2018

Vitamin B Deficiencies Can Show in Your Tongue
Wednesday, 24 Oct 2018

Casting Tape Market Competitive Strategies And Forecasts to 2026
Tuesday, 23 Oct 2018

Self-expandable Stents Market : Emerging Trends, Business Growth Opportunities, Major Driving Factor
Tuesday, 23 Oct 2018

Neonatal Intensive Care Unit (NICU) Services Market Size, Application Analysis, Regional Outlook, 20
Tuesday, 23 Oct 2018

Related Events

Targeted Protein Degradation Summit
Tuesday, 23 Oct 2018

Global Regulatory Affairs Summit
Tuesday, 23 Oct 2018

eyeforpharma Patient Summit USA
Tuesday, 23 Oct 2018

DKOU 2018 - German Congress of Orthopaedics and Traumatology
Tuesday, 23 Oct 2018

Assessing RET-Altered Tumors for Personalized Oncology Care, Oct 23
Tuesday, 23 Oct 2018

Latest News

Free Dating Site In USA Are The Solution For Singles To Meet Each Other Online
Wednesday, 24 Oct 2018

Eyesight Announces $15 Million Growth Round
Wednesday, 24 Oct 2018

Safetyone Ingegneria Srl Ensures Health and Safety at Construction Sites
Wednesday, 24 Oct 2018

Best Chance to Gain Clue Scroll with Up to 9% off rs3 gold on Count Check Until 10.31
Wednesday, 24 Oct 2018

Some Tips to Enjoy OSRS Skill: Warding with Up to 9% off runescape07 gold Until 10.31
Wednesday, 24 Oct 2018

Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Wednesday, 24 October 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Consumer Technology
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
News & Media
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!

Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.

  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.

  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Automotive And Vehicle Cost Engineering 2018 | Detroit, Conference
  • Targeted Protein Degradation Summit
  • Global Regulatory Affairs Summit
  • eyeforpharma Patient Summit USA
  • Cloud Security Summit

  • Latest Jobs
    Sorry, there are currently no entries posted here.